| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Division of Endocrinology, Departments of Medicine and Pediatrics, Harbor-University of California Los Angeles Medical Center (R.S.S., C.W., N.B., B.S.), Torrance, California 90509; and Division of Endocrinology, Department of Medicine, Veterans Administration Puget Sound Health Care System (C.J.B., B.D.A., W.J.B.), Seattle, Washington 98108
Address all correspondence and requests for reprints to: R. S. Swerdloff, Division of Endocrinology, Harbor-University of California Los Angeles Medical Center, 1000 West Carson Street, Torrance, California 90509. E-mail: Swerdloff{at}gcrc.humc.edu
GnRH antagonists plus testosterone (T) suppress LH and FSH levels and inhibit spermatogenesis to azoospermia or severe oligozoospermia. High-dose T treatment alone has been shown to be an effective male contraceptive (contraceptive efficacy rate of 1.4 per 100 person yr). Combined GnRH antagonist and T induces azoospermia more rapidly and at a higher incidence than T alone; this combination has therefore been proposed as a prototype male contraceptive. However, because GnRH antagonists are expensive to synthesize and difficult to deliver, it would be desirable to rapidly suppress sperm counts to low levels with GnRH antagonist plus T and maintain azoospermia or severe oligozoospermia with T alone. In this study, 15 healthy men (age 21–41 yr) with normal semen analyses were treated with T enanthate (TE) 100 mg im/week plus 10 mg Nal-Glu GnRH antagonist sc daily for 12 weeks to induce azoospermia or severe oligozoospermia. At 12–16 weeks, 10 of 15 subjects had zero sperm counts, and 14 of 15 had sperm counts less than 3 x 106/mL. The 14 who were suppressed on combined treatment were maintained on TE alone (100 mg/week im) for an additional 20 weeks. Thirteen of 14 subjects in the TE alone phase had sperm counts maintained at less than 3 x 106/mL for 20 weeks. Ten remained persistently azoospermic or had sperm concentration of 0.1 x 106/mL once during maintenance. Mean LH and FSH levels in the subjects were suppressed to 0.4 ± 0.2 IU/L and 0.5 ± 0.2 IU/L in the induction phase, which was maintained in the maintenance phase. The 1 subject who failed to suppress sperm counts during induction had serum LH and FSH reduced to 0.3 and 0.5 IU/L, respectively. The subject who failed to maintenance had LH and FSH suppressed to 1.0 and 0.2 IU/L, respectively, during the induction phase but these rose to 1.6 and 2.1 IU/L, respectively, during maintenance. Failure to suppress or maintain low sperm counts may be related to incomplete suppression of serum LH and FSH levels. We conclude that sperm counts suppressed with GnRH antagonist plus T can be maintained with relatively low dose TE treatment alone. This concept should be explored further in the development of effective, safe, and affordable hormonal male contraceptives.
This article has been cited by other articles:
 |
|
 |
|
  P. Y. Liu and R. I. McLachlan Male Hormonal Contraception: So Near and Yet So Far J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2474 - 2476. [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Page, J. K. Amory, and W. J. Bremner Advances in Male Contraception Endocr. Rev., June 1, 2008; 29(4): 465 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Liu, R. S. Swerdloff, B. D. Anawalt, R. A. Anderson, W. J. Bremner, J. Elliesen, Y.-Q. Gu, W. M. Kersemaekers, Robert. I. McLachlan, M. C. Meriggiola, et al. Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1774 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Page, J. K. Amory, B. D. Anawalt, M. S. Irwig, A. T. Brockenbrough, A. M. Matsumoto, and W. J. Bremner Testosterone Gel Combined with Depomedroxyprogesterone Acetate Is an Effective Male Hormonal Contraceptive Regimen and Is Not Enhanced by the Addition of a GnRH Antagonist J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4374 - 4380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Walton, R. A. L. Bayne, I. Wallace, D. T. Baird, and R. A. Anderson Direct Effect of Progestogen on Gene Expression in the Testis during Gonadotropin Withdrawal and Early Suppression of Spermatogenesis J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2526 - 2533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Matthiesson and R. I. McLachlan Male hormonal contraception: concept proven, product in sight? Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lue, C. Wang, Y.-X. Liu, A. P. S. Hikim, X.-S. Zhang, C.-M. Ng, Z.-Y. Hu, Y.-C. Li, A. Leung, and R. S. Swerdloff Transient Testicular Warming Enhances the Suppressive Effect of Testosterone on Spermatogenesis in Adult Cynomolgus Monkeys (Macaca fascicularis) J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 539 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Meriggiola, A. Costantino, F. Saad, L. D'Emidio, A. M. Morselli Labate, A. Bertaccini, W. J. Bremner, I. Rudolph, M. Ernst, B. Kirsch, et al. Norethisterone Enanthate Plus Testosterone Undecanoate for Male Contraception: Effects of Various Injection Intervals on Spermatogenesis, Reproductive Hormones, Testis, and Prostate J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2005 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Hay, B. M. Brady, M. Zitzmann, K. Osmanagaoglu, P. Pollanen, D. Apter, F. C. W. Wu, R. A. Anderson, E. Nieschlag, P. Devroey, et al. A Multicenter Phase IIb Study of a Novel Combination of Intramuscular Androgen (Testosterone Decanoate) and Oral Progestogen (Etonogestrel) for Male Hormonal Contraception J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2042 - 2049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Matthiesson, J. K. Amory, R. Berger, A. Ugoni, R. I. McLachlan, and W. J. Bremner Novel Male Hormonal Contraceptive Combinations: The Hormonal and Spermatogenic Effects of Testosterone and Levonorgestrel Combined with a 5{alpha}-Reductase Inhibitor or Gonadotropin-Releasing Hormone Antagonist J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 91 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-Labate, B. Kirsch, A. Bertaccini, C. Pelusi, and G. Pelusi Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5818 - 5826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Meriggiola, T. M.M. Farley, and M. T. Mbizvo A Review of Androgen-Progestin Regimens for Male Contraception J Androl, July 1, 2003; 24(4): 466 - 483. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Anderson and D. T. Baird Male Contraception Endocr. Rev., December 1, 2002; 23(6): 735 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.A. Anderson, Z.M. van der Spuy, O.A. Dada, S.K. Tregoning, P.M. Zinn, O.A. Adeniji, T.A. Fakoya, K.B. Smith, and D.T. Baird Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone Hum. Reprod., November 1, 2002; 17(11): 2869 - 2877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Anderson, D. Kinniburgh, and D. T. Baird Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Herbst, B. D. Anawalt, J. K. Amory, and W. J. Bremner Acyline: The First Study in Humans of a Potent, New Gonadotropin-Releasing Hormone Antagonist J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3215 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Narula, Y.-Q. Gu, L. O'Donnell, P. G. Stanton, D. M. Robertson, R. I. McLachlan, and W. J. Bremner Variability in Sperm Suppression during Testosterone Administration to Adult Monkeys Is Related to Follicle Stimulating Hormone Suppression and Not to Intratesticular Androgens J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3399 - 3406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kamischke, T. Heuermann, K. Kruger, S. von Eckardstein, I. Schellschmidt, A. Rubig, and E. Nieschlag An Effective Hormonal Male Contraceptive Using Testosterone Undecanoate with Oral or Injectable Norethisterone Preparations J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 530 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.M. Behre, S. Kliesch, B. Lemcke, S. von Eckardstein, and E. Nieschlag Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone Hum. Reprod., December 1, 2001; 16(12): 2570 - 2577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Martin, S. C. Riley, D. Everington, N. P. Groome, R. A. Riemersma, D. T. Baird, and R. A. Anderson Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men Hum. Reprod., July 1, 2000; 15(7): 1515 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lue, A. P. Sinha Hikim, C. Wang, M. Im, A. Leung, and R. S. Swerdloff Testicular Heat Exposure Enhances the Suppression of Spermatogenesis by Testosterone in Rats: The "Two-Hit" Approach to Male Contraceptive Development Endocrinology, April 1, 2000; 141(4): 1414 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kamischke, S. Venherm, D. Plöger, S. von Eckardstein, and E. Nieschlag Intramuscular Testosterone Undecanoate and Norethisterone Enanthate in a Clinical Trial for Male Contraception J. Clin. Endocrinol. Metab., January 1, 2000; 86(1): 303 - 309. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
